Recommend Products

Special Offer

Bulk Products

New Arrivals

Hot Sales

Publication Products

Special Offer

Chemical Structure Cat. No. Product Name CAS No.
3,4-Diaminofurazan Chemical Structure
BCP00227 3,4-Diaminofurazan 17220-38-1
3,4-Diaminofurazan is a building block used to prepare magnesium and zinc alkynylated salicylaldehyde-diamine Schiff base complexes.
Adavosertib Chemical Structure
BCP01928 Adavosertib 955365-80-7
MK-1775 is a potent and selective Wee1 kinase inhibitor with an IC50 of 5.2 nM.
WZ4002 Chemical Structure
BCP02515 WZ4002 1213269-23-8
WZ4002 is an EGFR T790M inhibitor(IC50<20nM).
Ivacaftor Chemical Structure
BCP01857 Ivacaftor 873054-44-5
Ivacaftor is a CFTR activator (IC50 of 43 ± 38 nM).
Dactolisib Chemical Structure
BCP00216 Dactolisib 915019-65-7
BEZ235 (NVP-BEZ235) inhibits PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes. The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin inhibitor (mTOR) pathway is often constitutively activated in human tumor cells.
Vistusertib Chemical Structure
BCP05748 Vistusertib 1009298-59-2
AZD2014 is a selective inhibitor of mTOR kinase. AZD2014 decreases p4EBP1 Thr37/46, inhibits the translation initiation complex and decreases overall protein synthesis. AZD2014 also inhibits the mTORC2 biomarkers pAKTSer473 and pNDRG1 Thr346. AZD2014 inhibits proliferation and induces cell death in breast cancer cell lines, including ER+ cell lines with acquired resistance to hormone therapy.
Tezacaftor Chemical Structure
BCP07173 Tezacaftor 1152311-62-0
Tezacaftor, also known asVX-661, is CFTR modulator. VX-661 is potentially useful for treatment of cystic fibrosis disease. Cystic fibrosis (CF) is a genetic disease caused by defects in the CF transmembrane regulator (CFTR) gene, which encodes an epithelial chloride channel. The most common mutation, Δ508CFTR, produces a protein that is misfolded and does not reach the cell membrane. VX-661 can correct trafficking of Δ508CFTR and partially restore chloride channel activity.
Dolutegravir Chemical Structure
BCP02329 Dolutegravir 1051375-16-6
Dolutegravir is an integrase inhibitor being developed for the treatment of human immunodeficiency virus (HIV)-1 infection by GlaxoSmithKline (GSK) on behalf of Shionogi-ViiV Healthcare LLC.
Galunisertib Chemical Structure
BCP02173 Galunisertib 700874-72-2
LY2157299 is a novel selective small molecule transforming growth factor beta receptor (TGF-βR) kinase inhibitor with IC50 of 86 nM and 2 nM for TβR1 and 2 nM, respectively.
Bedaquiline Chemical Structure
BCP02829 Bedaquiline 843663-66-1
Bedaquiline, also known as TMC207 and R207910, is a diarylquinoline anti-tuberculosis drug.
APR-246 Chemical Structure
BCP20294 APR-246 5291-32-7
APR-246 restores wild-type conformation and function to mutant p53, and triggers apoptosis in tumor cells. PRIMA-1Met also targets the selenoprotein thioredoxin reductase 1 (TrxR1), a key regulator of cellular redox balance.
Trichostatin A Chemical Structure
BCP01776 Trichostatin A 58880-19-6
Trichostatin A is a selective and potent inhibitor of histone deacetylase (Ki = 3.4 nM).
EAI045 Chemical Structure
BCP17698 EAI045 1942114-09-1
EAI045 is an allosteric inhibitor that targets selected drug-resistant EGFR mutants.
Roxadustat Chemical Structure
BCP02523 Roxadustat 808118-40-3
Roxadustat (FG-4592) is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor developed for the treatment of anemia.
Etomoxir Chemical Structure
BCP07911 Etomoxir 124083-20-1
Etomoxir is a potent inhibitor of carnitine palmitoyltransferase-I (CPT-1).
LOXO-195 Chemical Structure
BCP20662 LOXO-195 2097002-61-2
LOXO-195 is a next-generation TRK kinase (TKI) inhibitor, with IC50s of 0.6±0.1 nM, <2.5 nM for TRKA and TRKC respectively.
BMS986205 Chemical Structure
BCP20339 BMS986205 1923833-60-6
BMS-986205 is a selective indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor.
CAL-101 Chemical Structure
BCP02532 CAL-101 870281-82-6
CAL-101 is a potent PI3K p110δ inhibitor with an IC50 of 65 nM.
Physostigmine salicylate Chemical Structure
BCP25378 Physostigmine salicylate 57-64-7
Physostigmine salicylate is a reversible cholinesterase inhibitor, a parasympathomimetic alkaloid.
GSK2330672 Chemical Structure
BCP17155 GSK2330672 1345982-69-5
GSK2330672 is a highly potent, nonabsorbable ASBT(apical sodium-dependent bile acid transporter) inhibitor (hASBT IC50=42 ± 3 nM) which lowers glucose in an animal model of type 2 diabetes and shows excellent developability properties for evaluating the potential therapeutic utility of a nonabsorbable ASBT inhibitor for treatment of patients with type 2 diabetes.
12下一页共 31 条记录 1 / 2 页